Stevanato Group (STVN) 2026 KeyBanc Capital Markets Healthcare Forum summary

Business overview and market positioning

• Delivers mission-critical solutions for biopharma and diagnostics, with 88% of revenue from Biopharmaceutical and Diagnostic Solutions (BDS) and 12% from Engineering.

• Offers a broad portfolio including pharmaceutical glass products, high-value solutions like Nexa, Alba, and EZ-fill Smart, and drug delivery platforms.

• Maintains long-term customer relationships due to integration in regulatory filings and high switching costs.

• Market leader in pen cartridges and ready-to-use vials, and second in prefilled syringes.

• Consistent double-digit organic growth and margin expansion over 20 years, driven by high-value solutions.

Financial performance and guidance

• Achieved 9% constant currency growth in 2025, with high-value solutions growing ~30% YoY and representing 46% of revenue.

• Nexa prefilled syringes were the fastest-growing product, with GLP-1-related revenue up over 50% and accounting for 19%-20% of total revenue.

• Expanded gross profit margin by 160 bps and operating margin by 220 bps in 2025; expects 8%-10% top-line growth in 2026.

• Adjusted EBITDA margin projected to expand by 150 bps in 2026, with high-value solutions reaching 47%-48% of revenue.

• Q4 2025 saw 7% constant currency growth, with high-value solutions up 31% YoY and margins expanding 120 bps.

Segment and product trends

• Vial market showed 6% growth in 2025, led by sterile vials; further mid- to high-single-digit growth expected in 2026.

• 40% increase in biologics customers outside GLP-1, with strong traction in monoclonal antibodies and biosimilars, especially in Asia-Pacific.

• GLP-1 revenue growth expected to normalize to mid-teens in 2026 after a strong ramp-up phase.

• Focus on expanding high-value product share and improving profitability at new greenfield plants.